Navigation Links
Amarin Provides 2010 Year-End Review to Shareholders
Date:1/31/2011

DUBLIN and MYSTIC, Conn., Jan. 31, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today issued a special letter to its shareholders. The text of the letter, written by Joseph S. Zakrzewski, Executive Chairman and Chief Executive Officer of Amarin, follows:

Dear Shareholders:

With 2011 now underway, I am pleased to provide you with a brief review of Amarin's accomplishments in 2010 and an outline of our strategy for 2011 and beyond. In summary, 2010 was a very successful year for us, and we look forward to continued success in the year to come.

Our Recent Accomplishments Include:

  • Successful top-line results from our Phase 3 MARINE trial
  • Completed patient randomization for our Phase 3 ANCHOR trial
  • Strengthened management team and board of directors
  • Strengthened balance sheet with additional $100M cash
  • On track for a 2011 NDA submission

  • AMR101 is Positioned to Be Best-in-Class Therapy for Very High TriglyceridesIn November 2010, we announced that AMR101, Amarin's lead product candidate for the treatment of patients with very high triglycerides (>500 mg/dL), met the primary endpoint in the Phase 3 MARINE study with highly significant reductions in triglycerides from baseline compared to placebo at both the 4 gram and 2 gram doses. In addition to achieving these key endpoints, the results of this trial exceeded our expectations with no statistically significant increase in LDL-cholesterol observed at either dose, with triglyceride lowering that was greater in the predefined subset of patients on statin therapy and with encouraging results regarding prespecified markers of inflammation. Additionally, we observed in the trial a safety profile for AMR101 similar to placebo. The endpoints for this trial were establishe
    '/>"/>

    SOURCE Amarin Corporation plc
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
    2. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
    3. Amarin to Present at UBS Life Sciences Conference
    4. Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
    5. Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
    6. Amarin Prices Public Offering of American Depositary Shares
    7. Amarin Announces Underwriters Exercise of Over-Allotment Option
    8. Amarin Announces Successful Completion of Offering of American Depositary Shares
    9. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
    10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)... REDWOOD CITY, Calif. , Aug. 27, 2014 ... in emergency response system design, blended emergency medical ... for CPR/AED (automated external defibrillator) training from the ... and the Army Reserve 81 st ... Homeland Security and Investigations contract includes nationwide CPR/AED/First ...
    (Date:8/27/2014)... WARSAW, Ind. , Aug. 27, 2014  Zimmer ... in musculoskeletal care, announced that it will be participating ... the Grand Hyatt in New York, New ... David Dvorak , President and CEO of Zimmer, will ... Binder , President and CEO of Biomet, will join ...
    (Date:8/27/2014)... Aug. 27, 2014 Asterias Biotherapeutics Inc. (OTCBB: ... Drug Administration (FDA) to initiate a Phase 1/2a clinical ... cervical spinal cord injury.  The approved trial follows the ... the product, and is designed to assess safety and ... complete cervical spinal cord injuries, the first targeted indication ...
    Breaking Medicine Technology:Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5
    ... 15, 2012  Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company ... cells (CSCs) and tumor bulk, today announced that Kevin ... Since serving as Chief Executive Officer of Cephalon, Inc. ... (Nasdaq: TEVA ) in October 2011, Mr. ...
    ... IRVINGTON, N.Y., March 15, 2012  ORTHOCON®, Inc., a ... J. Hart has been appointed Vice President of ... in-licensing and acquiring new products and technologies for ... teams.  Mr. Hart joins ORTHOCON ...
    Cached Medicine Technology:Stemline Therapeutics Appoints Kevin Buchi, Former CEO of Cephalon, to Its Board of Directors 2ORTHOCON® Names David J. Hart Vice President of Business Operations 2
    (Date:8/27/2014)... Amy Norton HealthDay Reporter , ... part in clinical trials of new heart disease treatments are ... new study confirms. Experts said the findings, which appear ... Association , aren,t surprising -- but they are troubling. ... more select patient population that is not fully representative of ...
    (Date:8/27/2014)... from our parents shapes many aspects of our lives. ... epigenome that is set during development, but can be ... by those of our parents and grandparents. , The ... supporting proteins that determine whether genes are expressed or ... our own health, but also that it may be ...
    (Date:8/27/2014)... spending for commercially insured individuals is due primarily to ... use, according to a new study led by researchers ... Practice, published in the August issue of the ... increasing concern that consolidation in the health care marketplace ... ultimately, consumers," said Carrie Colla, PhD, assistant professor at ...
    (Date:8/27/2014)... 27, 2014 CarePoint Health is ... Hoboken Pediatrics has joined our network, CarePoint Health ... Dr. Piotr Oko, Dr. Yanina Meshko and Dr. ... skilled and experienced physicians comprise CarePoint Health Medical ... practices in Hudson County, representing a wide range ...
    (Date:8/27/2014)... Scientists at The Scripps Research Institute (TSRI) have ... can be associated with alcohol dependence. , This ... type 1 (Nf1), which TSRI scientists found is linked ... Nf1 regulates gamma-aminobutyric acid (GABA), a neurotransmitter that lowers ... novel and seminal study provides insights into the cellular ...
    Breaking Medicine News(10 mins):Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 4Health News:Tracking spending among the commercially insured 2Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 2Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2
    ... could deter more than 100,000 Californians from enrolling in ... today by the California Pan-Ethnic Health Network, the UCLA ... Center for Labor Research and Education. ... that estimates the likely enrollment in health care reform ...
    ... , WEDNESDAY, Feb. 29 (HealthDay News) -- Federal ... helped provide guidance on whether it,s safe or effective for ... The Institute of Medicine (IOM) report noted, however, ... drugs in newborns or the long-term effects of drugs on ...
    ... people with diabetes could be adapted into a home DNA ... and bacteria in human body fluids, in food and in ... report on this adaptation of the ubiquitous personal glucose monitor, ... journal Analytical Chemistry . Yi Lu and Yu ...
    ... (FDA) announced it is revising safety information on the labels ... class of drugs that work in the liver to prevent ... at lowering the LDL (bad) cholesterol, but also have modest ... cholesterol. High cholesterol is a risk factor for ...
    ... HealthDay Reporter , TUESDAY, Feb. 28 (HealthDay News) ... emergency room with fevers are making the right decision, ... not be generalized, and therefore not approached, as a ... Dr. Yvette van Ierland, from the department of pediatrics ...
    ... , TUESDAY, Feb. 28 (HealthDay News) -- Taking the ... fetus and lead to poorer motor control in infants, a ... their substance-abuse history before and during pregnancy. The women were ... Infancy Study, which looks at recreational drug use among pregnant ...
    Cached Medicine News:Health News:Study: Over 100,000 Californians likely to miss out on health care due to language barriers 2Health News:Efforts to Improve Research on Kids' Drugs Paying Off: Report 2Health News:American Heart Association comment: FDA announces safety changes on labeling for some statins 2Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 2Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 3Health News:Ecstasy Use During Pregnancy May Harm Fetus: Study 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: